Abstract
The current way to increase efficacy of cancer therapy is the use of molecular recognition of aberrantly expressed gene products for selective treatment. However, only a fraction of the patients have tumors with a particular molecular target. Radionuclide imaging of molecular targets might help to stratify patient for cancer treatment. Affibody molecules are scaffold proteins, which can be selected for high affinity recognition of proteinaceous molecular targets. The capacity to re-fold under physiological conditions allows labeling of Affibody molecules in a broad range of pH and temperatures with preserved binding properties. Peptide synthesis or introduction of a unique cysteine enables sitespecific labeling of Affibody molecules, resulting in uniform conjugates with well-defined pharmacological characteristics. The small size (7 kDa) of Affibody molecules provides rapid extravasation, rapid tumor penetration, and rapid clearance of unbound tracer from healthy organs and tissues. In combination with sub-nanomolar affinity, this results in high contrast in vivo imaging a few hours after injection. Excellent targeting has been demonstrated in pre-clinical studies with HER2-targeting Affibody molecules labeled with 99mTc and 111In for single photon computed tomography (SPECT), and 18F, 64Cu, 124I and 68Ga for positron emission tomography (PET). Pilot clinical data confirm the high potential of Affibody molecules.
Keywords: Affibody molecules, EGFR, HER2, molecular imaging, radionuclide, scaffold proteins, targeting
Current Pharmaceutical Biotechnology
Title: Radionuclide Molecular Imaging Using Affibody Molecules
Volume: 11 Issue: 6
Author(s): Sara Ahlgren and Vladimir Tolmachev
Affiliation:
Keywords: Affibody molecules, EGFR, HER2, molecular imaging, radionuclide, scaffold proteins, targeting
Abstract: The current way to increase efficacy of cancer therapy is the use of molecular recognition of aberrantly expressed gene products for selective treatment. However, only a fraction of the patients have tumors with a particular molecular target. Radionuclide imaging of molecular targets might help to stratify patient for cancer treatment. Affibody molecules are scaffold proteins, which can be selected for high affinity recognition of proteinaceous molecular targets. The capacity to re-fold under physiological conditions allows labeling of Affibody molecules in a broad range of pH and temperatures with preserved binding properties. Peptide synthesis or introduction of a unique cysteine enables sitespecific labeling of Affibody molecules, resulting in uniform conjugates with well-defined pharmacological characteristics. The small size (7 kDa) of Affibody molecules provides rapid extravasation, rapid tumor penetration, and rapid clearance of unbound tracer from healthy organs and tissues. In combination with sub-nanomolar affinity, this results in high contrast in vivo imaging a few hours after injection. Excellent targeting has been demonstrated in pre-clinical studies with HER2-targeting Affibody molecules labeled with 99mTc and 111In for single photon computed tomography (SPECT), and 18F, 64Cu, 124I and 68Ga for positron emission tomography (PET). Pilot clinical data confirm the high potential of Affibody molecules.
Export Options
About this article
Cite this article as:
Ahlgren Sara and Tolmachev Vladimir, Radionuclide Molecular Imaging Using Affibody Molecules, Current Pharmaceutical Biotechnology 2010; 11 (6) . https://dx.doi.org/10.2174/138920110792246609
DOI https://dx.doi.org/10.2174/138920110792246609 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Nitro-Heterocycles Sugar and Indoles Candidates as Lead Structures Targeting HepG2 and A549 Cancer Cell Lines
Current Bioactive Compounds Fractalkine/CX3CR1 Signalling in Chronic Pain and Inflammation
Current Pharmaceutical Biotechnology Cytokine Status of Serum in Ovarian Cancer Patients with Different Tumor Neoadjuvant Chemotherapy Response
Anti-Cancer Agents in Medicinal Chemistry Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes
Current Pharmaceutical Design New Opportunities for Pregnane X Receptor (PXR) Targeting in Drug Development. Lessons from Enantio- and Species-Specific PXR Ligands Identified from A Discovery Library of Amino Acid Analogues
Mini-Reviews in Medicinal Chemistry Small Peptides as Modulators of Serine Proteases
Current Medicinal Chemistry Preface
Current Signal Transduction Therapy <i>In Vitro</i> Anti-proliferative Properties of Flavonoids Isolated from <i>Artocarpus Heterophyllus</i> on Cancer Cell Lines
The Natural Products Journal Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry CCL21 and IFNγ Recruit and Activate Tumor Specific T cells in 3D Scaffold Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Microstrip Antenna-inception, Progress and Current-state of The Art Review
Recent Advances in Electrical & Electronic Engineering Developments of Polo-like Kinase 1 (Plk1) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Elucidation of the Chemopreventive Role of Stigmasterol Against Jab1 in Gall Bladder Carcinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Development of In Vitro Co-Culture Model in Anti-Cancer Drug Development Cascade
Combinatorial Chemistry & High Throughput Screening Cardiac Fat as New Diagnostic Tool and Potential Therapeutic Target for Obesity Management and Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Conjugation of Peptides to Antisense Interleukin-6 Via Click Chemistry
Current Medicinal Chemistry Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Cytokine Gene Polymorphisms in Cancer and Inflammatory Disorders
Current Immunology Reviews (Discontinued) New Insights of CTLA-4 into Its Biological Function in Breast Cancer
Current Cancer Drug Targets Predictive Factors of Febrile Neutropenia Induced by Anticancer Chemotherapy in the South of Tunisia
Reviews on Recent Clinical Trials